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Naming Treatment in semantic and logopenic variant PPA 
  
 Primary progressive aphasia (PPA) is an acquired impairment of language 
caused by neurodegenerative disease affecting language regions in the brain. Unlike 
aphasia caused by stroke, the language impairments in PPA gradually worsen over time 
as atrophy spreads. Current consensus criteria for diagnosis identify three clinical 
variants, each of which is associated with a different pathological entity: a semantic 
variant, with verbal and nonverbal semantic deficits; a logopenic variant, with anomia 
and phonological working memory problems; and a nonfluent variant, with agrammatism 
and/or apraxia of speech (Gorno-Tempini et al., 2011; Gorno-Tempini et al., 2004). 
 Naming impairment is common to both lv and svPPA, however the nature of the 
deficit differs across these two syndromes. The naming impairment in lvPPA occurs as 
a result of damage to the phonological system, likely affecting phonological assembly or 
retrieval. SvPPA, on the other hand, is characterized by dramatically impaired naming in 
the context of a generalized semantic deficit affecting both linguistic and non-linguistic 
domains. Thus, anomia in svPPA is a result of damage to the semantic system, 
whereas anomia in lvPPA results from damage/access to phonological representations.  
Relative to individuals with aphasia caused by stroke, individuals with PPA are 
less likely to receive treatment for speech and language deficits and there are far fewer 
studies examining speech-language treatment in PPA. The existing treatment literature 
focuses largely on remediation of naming and, of those studies, the majority of treated 
patients have had svPPA. There are only a couple of studies examining naming 
treatment in patients with lvPPA, despite the fact that naming impairment is a prominent 
deficit in these patients.  
In this study, we administered treatment for lexical retrieval in one patient with 
lvPPA and one with svPPA. The two treatments were similar but not identical, with 
modifications in order to maximize treatment gains, given the distinct levels of cognitive-
linguistic breakdown in the two syndromes. 
Methods 
Participants 
Two individuals with PPA were identified via consensus diagnosis following 
comprehensive testing at the Memory and Aging Center (MAC). Diagnostic testing 
included neurological and neuropsychological examinations as well as extensive 
language testing. Structural MRI scans were also obtained. Consistent with current 
diagnostic guidelines, following PPA diagnosis, individuals were subsequently 
diagnosed by variant. One individual, presenting with relatively fluent spoken language 
with pauses for word-finding, occasional phonemic paraphasias, spared object 
knowledge, motor speech, and syntax, was diagnosed with lvPPA (hereafter, LV).  MRI 
revealed left temporo-parietal atrophy (Figure 1). The second individual, presenting with 
fluent speech, marked anomia, single-word comprehension deficits, impaired object 
knowledge, and spared syntax and motor speech, was diagnosed with svPPA 
(hereafter, SV). MRI revealed left greater than right atrophy in the anterior temporal 
lobes.  
Assessment and treatment target selection 
Individuals underwent language testing pre-treatment, post-treatment, and in the 
case of LV, at three and six months post-treatment (Table 1). SV was not available for 
follow-up testing due to illness. Treatment targets were selected for LV by asking her to 
name color pictures of objects on three separate occasions. Items that she could not 
name on at least two of the three occasions were selected for treatment. Five sets of 
five items were selected, with each set balanced with other sets for word length, number 
of syllables, number of phonemes, imeageability, and frequency. One set was not 
trained and served as a control set.  
Previous research indicates that relearning of lexical targets in SV is more 
feasible with items for which there is some degree of residual semantic knowledge. For 
this reason, treatment targets for SV were selected from amongst the patient’s own 
possessions in her home (color photographs were taken of actual items). Items that 
could not be named on at least two of three consecutive occasions were eligible for 
treatment. Again, 20 items (in four matched sets of 5) were selected for treatment and 
one set of five items was selected as a control set. 
Treatment methods 
The in-session treatment protocol involved semantic, phonologic, and 
orthographic cueing. The protocol was similar across the two patients (see Table 2), but 
with some important differences. First, LV was trained in semantic circumlocution, 
whereas SV was asked to state two features only, one of which was a “personal” 
association, rather than a generic semantic feature. Secondly, LV was provided with 
first letter/sound in hopes of cueing production. Given that phonological/orthographic 
cueing is rarely productive in SV, our patient was provided written choices to select from 
(with semantically or phonologically/orthographically-similar foils). Both participants 
were asked to make semantic judgments regarding statements made by the clinician, 
then to re-state two features and provide spoken and written targets from memory. 
Treatment sets were trained to an 80% criterion, with one hour-long session per week. 
Daily homework was administered to provide supplemental rehearsal of spoken 
and written targets. Homework consisted of Copy and Recall Treatment (CART; 
Beeson, 1999; Beeson et al., 2002; Beeson et al., 2003) with a repetition component 
(Beeson & Egnor, 2006). Individuals were provided a picture of the target and its written 
word form. They copied the written word 10 times and, after each written production, 
were asked to produce the spoken word form (with a model provided by a “talking” 
photo album for the SV participant). After ten productions, they were asked to turn over 
the paper and say/write the target from memory. This was repeated for each of the five 
targets undergoing treatment at a given time.  
 
 
Results 
Treatment data for trained and untrained items are shown in Figures 2 and 3. LV 
demonstrated a significant change in performance from pre- to post- treatment (p<.001) 
and pre- to three and six month follow-ups (ps<.001) for spoken production of trained 
items. Written production of those items also changed significantly. SV demonstrated a 
significant change in performance from pre- to post-treatment (p<.001) and from pre- to 
one month post-treatment (p<.001) for trained items. Performance was identical for both 
written and spoken production. Standardized tests (Table 1) revealed a gradual decline 
in overall language performance from pre-treatment to six months post-treatment for LV. 
Her confrontation naming improved slightly at post-treatment and Mini-Mental State 
Exam (MMSE) and Pyramids and Palm Trees Test (PPT) remained stable from pre- to 
post-treatment. SV showed a decline in overall language performance from pre- to post-
treatment as well as a slight decline on naming and nonverbal semantic measures. 
MMSE also declined significantly. Both patients showed no impairment of motor speech 
(MSE).  
Discussion 
Results indicate that individuals with two variants of PPA can benefit from 
treatment for lexical retrieval. Successful outcomes were likely enhanced by 
modifications to the treatment regime based on the cognitive profile of each participant. 
Individuals with lvPPA can capitalize on spared semantic processing to improve 
phonological retrieval, whereas patients with svPPA should be encouraged to retrieve 
residual conceptual knowledge in conjunction with phonological and orthographic 
rehearsal. Our study examined simultaneous training for spoken and written naming in 
PPA, each of which benefited from intervention. Our LV case shows that these gains 
may be lasting (up to six months post-treatment). The participant with SV maintained 
gains up to one month post-treatment; however, information regarding maintenance 
beyond this time frame awaits future research. 
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Table 1. Pre- and post-treatment test results 
 
WAB-
pre 
WAB-
post 
WAB-
3 
mos 
WAB-
6 
mos 
BNT-
pre 
BNT-
post 
PPT-
pre 
PPT-
post 
MSE-
pre 
MSE-
post 
MMSE-
pre 
MMSE-
post 
lvPPA 80 75.2 73.9 68.8 27 31 49 48 
AOS-0, 
Dys-0 
AOS-0, 
Dys-0 15 15 
svPPA 65.9 60.7 N/A N/A 3 2 37 35 
AOS-0, 
Dys-0 
AOS-0, 
Dys-0 25 17 
WAB=Western Aphasia Battery, BNT=Boston Naming Test, PPT=Pyramids and Palm Trees Test (picture version), MSE=Motor 
Speech Evaluation (from Wertz et al., 1984), MMSE=Mini-Mental State Exam      
      
Table 2. Treatment protocols 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LV Treatment Protocol SV Treatment Protocol 
1. A picture is placed in the center of the table in front of 
the participant and cards reading “is a kind of ________”, 
“is used for ________”, “does what?”, “has/is _____”,  “is 
found ______”, and “reminds me of_______” are placed 
around the item. The participant is asked to name the item 
and, regardless of whether the item is named, is 
subsequently guided through enumeration of the semantic 
features of the target (group, use, action, attributes/parts, 
location, and association). 
1. A target picture is shown to the participant, who is asked 
to retrieve one personal (e.g., my daughter gave me that) 
and one generic (e.g., used for sitting on) semantic feature. 
2. If participant can’t name the target, written first letter and 
spoken first sound are provided as cues. If the item still is 
not named, a written and spoken model are given and 
repeated by the participant x3. 
2. If participant can’t name the target, four written choices 
are provided (the target and three semantically and/or 
phonologically-related foils). Following selection of the item 
(if correct; if incorrect, the participant is shown the correct 
item), written and spoken production are elicited x3. 
3. The participant is asked to make a judgment regarding 
the semantic plausibility of five sentences regarding the 
target (written and spoken presentation by the clinician). 
Some sentences will be semantically correct (e.g., “A 
feather is soft and light”), while others violate some 
semantic feature of the target (e.g., “A feather is hard and 
heavy” violates attribute feature). 
3. The participant is asked to make a judgment regarding 
the semantic plausibility of five sentences using the target 
word (written and spoken presentation by the clinician). 
Some sentences will be semantically correct (e.g., “A 
toaster is something used to heat bread,” while others are 
semantically incorrect. (e.g., “A toaster is something used to 
dry clothes.”) 
4. The participant is asked to re-state two semantic 
features of the target and produce its spoken and written 
name. 
4. The participant is asked to re-state two semantic features 
of the target and produce its spoken and written name. 
Figure 1. MRI scans for LV and SV patients      
 
 
 
 
 
 
 
Figure 2 a,b. Treatment data for LV (note= untrained targets remained at zero throughout) 
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Figure 3. Treatment data for SV 
 
 
  
 
 
 
 
 
